Limits...
Use of a Guinea pig-specific transcriptome array for evaluation of protective immunity against genital chlamydial infection following intranasal vaccination in Guinea pigs.

Wali S, Gupta R, Veselenak RL, Li Y, Yu JJ, Murthy AK, Cap AP, Guentzel MN, Chambers JP, Zhong G, Rank RG, Pyles RB, Arulanandam BP - PLoS ONE (2014)

Bottom Line: Importantly, at day 80 post challenge, vaccinated guinea pigs experienced significantly reduced genital pathology - a sequelae of genital chlamydial infections, in comparison to mock vaccinated guinea pigs.Th1-cellular/inflammatory immune genes and Th2-humoral associated genes were also found to be elevated in vaccinated guinea pigs at day 3 post-challenge and correlated with early clearance of the bacterium.Overall, this study provides the first evidence of guinea pig-specific genes involved in anti-chlamydial vaccination and illustrates the enhancement of the utility of this animal model in chlamydial pathogenesis.

View Article: PubMed Central - PubMed

Affiliation: South Texas Center for Emerging Infectious Diseases and Center of Excellence in Infection Genomics, University of Texas at San Antonio, One UTSA Circle, San Antonio, Texas 78249, United Stats of America.

ABSTRACT
Guinea pigs have been used as a second animal model to validate putative anti-chlamydial vaccine candidates tested in mice. However, the lack of guinea pig-specific reagents has limited the utility of this animal model in Chlamydia sp. vaccine studies. Using a novel guinea pig-specific transcriptome array, we determined correlates of protection in guinea pigs vaccinated with Chlamydia caviae (C. caviae) via the intranasal route, previously reported by us and others to provide robust antigen specific immunity against subsequent intravaginal challenge. C. caviae vaccinated guinea pigs resolved genital infection by day 3 post challenge. In contrast, mock vaccinated animals continued to shed viable Chlamydia up to day 18 post challenge. Importantly, at day 80 post challenge, vaccinated guinea pigs experienced significantly reduced genital pathology - a sequelae of genital chlamydial infections, in comparison to mock vaccinated guinea pigs. Sera from vaccinated guinea pigs displayed antigen specific IgG responses and increased IgG1 and IgG2 titers capable of neutralizing GPIC in vitro. Th1-cellular/inflammatory immune genes and Th2-humoral associated genes were also found to be elevated in vaccinated guinea pigs at day 3 post-challenge and correlated with early clearance of the bacterium. Overall, this study provides the first evidence of guinea pig-specific genes involved in anti-chlamydial vaccination and illustrates the enhancement of the utility of this animal model in chlamydial pathogenesis.

Show MeSH

Related in: MedlinePlus

Vaccination of Guinea pigs with C. caviae Protects Against Genital Chlamydial Infection.Groups (5 per group) of guinea pigs were immunized i.n. with 1×105 IFU C. caviae or treated with PBS as mock vaccination controls. All animals were rested for 30 days and challenged i.vag. with 1×105 IFU C. caviae. Chlamydial shedding was monitored every third day after challenge for a month, and are presented as mean ± SD for each group at each time point.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263467&req=5

pone-0114261-g001: Vaccination of Guinea pigs with C. caviae Protects Against Genital Chlamydial Infection.Groups (5 per group) of guinea pigs were immunized i.n. with 1×105 IFU C. caviae or treated with PBS as mock vaccination controls. All animals were rested for 30 days and challenged i.vag. with 1×105 IFU C. caviae. Chlamydial shedding was monitored every third day after challenge for a month, and are presented as mean ± SD for each group at each time point.

Mentions: Intranasal vaccination of mice with C. muridarum EBs has been shown to provide robust protection against genital C. muridarum infection [11], [12]. To establish a similar vaccination regimen against i.vag. C. caviae infection in guinea pigs, we i.n. immunized guinea pigs with 1×105C. caviae EBs. Guinea pigs administrated PBS i.n. were used as a mock vaccination control, similar to studies in mice previously reported to be comparable to an adjuvant-alone control group [15]. All guinea pigs were rested for 30 days and i.vag. challenged with 1×105C. caviae EBs. As shown in Fig. 1, C. caviae EB vaccinated animals cleared the infection at day 3 post challenge whereas mock vaccinated guinea pigs shed C. caviae (1×106 inclusion forming units; IFU) for 6 days post challenge, followed by reduced bacterial loads from days 9–18, and no recoverable bacteria by day 21 post challenge.


Use of a Guinea pig-specific transcriptome array for evaluation of protective immunity against genital chlamydial infection following intranasal vaccination in Guinea pigs.

Wali S, Gupta R, Veselenak RL, Li Y, Yu JJ, Murthy AK, Cap AP, Guentzel MN, Chambers JP, Zhong G, Rank RG, Pyles RB, Arulanandam BP - PLoS ONE (2014)

Vaccination of Guinea pigs with C. caviae Protects Against Genital Chlamydial Infection.Groups (5 per group) of guinea pigs were immunized i.n. with 1×105 IFU C. caviae or treated with PBS as mock vaccination controls. All animals were rested for 30 days and challenged i.vag. with 1×105 IFU C. caviae. Chlamydial shedding was monitored every third day after challenge for a month, and are presented as mean ± SD for each group at each time point.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263467&req=5

pone-0114261-g001: Vaccination of Guinea pigs with C. caviae Protects Against Genital Chlamydial Infection.Groups (5 per group) of guinea pigs were immunized i.n. with 1×105 IFU C. caviae or treated with PBS as mock vaccination controls. All animals were rested for 30 days and challenged i.vag. with 1×105 IFU C. caviae. Chlamydial shedding was monitored every third day after challenge for a month, and are presented as mean ± SD for each group at each time point.
Mentions: Intranasal vaccination of mice with C. muridarum EBs has been shown to provide robust protection against genital C. muridarum infection [11], [12]. To establish a similar vaccination regimen against i.vag. C. caviae infection in guinea pigs, we i.n. immunized guinea pigs with 1×105C. caviae EBs. Guinea pigs administrated PBS i.n. were used as a mock vaccination control, similar to studies in mice previously reported to be comparable to an adjuvant-alone control group [15]. All guinea pigs were rested for 30 days and i.vag. challenged with 1×105C. caviae EBs. As shown in Fig. 1, C. caviae EB vaccinated animals cleared the infection at day 3 post challenge whereas mock vaccinated guinea pigs shed C. caviae (1×106 inclusion forming units; IFU) for 6 days post challenge, followed by reduced bacterial loads from days 9–18, and no recoverable bacteria by day 21 post challenge.

Bottom Line: Importantly, at day 80 post challenge, vaccinated guinea pigs experienced significantly reduced genital pathology - a sequelae of genital chlamydial infections, in comparison to mock vaccinated guinea pigs.Th1-cellular/inflammatory immune genes and Th2-humoral associated genes were also found to be elevated in vaccinated guinea pigs at day 3 post-challenge and correlated with early clearance of the bacterium.Overall, this study provides the first evidence of guinea pig-specific genes involved in anti-chlamydial vaccination and illustrates the enhancement of the utility of this animal model in chlamydial pathogenesis.

View Article: PubMed Central - PubMed

Affiliation: South Texas Center for Emerging Infectious Diseases and Center of Excellence in Infection Genomics, University of Texas at San Antonio, One UTSA Circle, San Antonio, Texas 78249, United Stats of America.

ABSTRACT
Guinea pigs have been used as a second animal model to validate putative anti-chlamydial vaccine candidates tested in mice. However, the lack of guinea pig-specific reagents has limited the utility of this animal model in Chlamydia sp. vaccine studies. Using a novel guinea pig-specific transcriptome array, we determined correlates of protection in guinea pigs vaccinated with Chlamydia caviae (C. caviae) via the intranasal route, previously reported by us and others to provide robust antigen specific immunity against subsequent intravaginal challenge. C. caviae vaccinated guinea pigs resolved genital infection by day 3 post challenge. In contrast, mock vaccinated animals continued to shed viable Chlamydia up to day 18 post challenge. Importantly, at day 80 post challenge, vaccinated guinea pigs experienced significantly reduced genital pathology - a sequelae of genital chlamydial infections, in comparison to mock vaccinated guinea pigs. Sera from vaccinated guinea pigs displayed antigen specific IgG responses and increased IgG1 and IgG2 titers capable of neutralizing GPIC in vitro. Th1-cellular/inflammatory immune genes and Th2-humoral associated genes were also found to be elevated in vaccinated guinea pigs at day 3 post-challenge and correlated with early clearance of the bacterium. Overall, this study provides the first evidence of guinea pig-specific genes involved in anti-chlamydial vaccination and illustrates the enhancement of the utility of this animal model in chlamydial pathogenesis.

Show MeSH
Related in: MedlinePlus